Enforcement Report - Week of November 17, 2021
Precision Dose, Inc. Issues Voluntary Nationwide Recall of Paroex Chlorhexidine Gluconate Oral Rinse
Precision oncology firm Notable Labs is launching its first self-sponsored clinical trial, designed from the ground up to help validate its cancer patient matching platform over the long term.
Singapore-based precision oncology startup Lucence, on the heels of its series A funding, is sharing early data highlighting the capabilities of its liquid biopsy technology to detect somatic variants in patients with blood cancers, with excellent matching between bone marrow and blood. Lucence’s amplicon-based sequencing technology, known as AmpliMARK™, can provide high sensitivity mutation detection in blood for multiple solid tumor types. This new study data demonstrates the performance of AmpliMARK™ in hematological malignancies, and suggests that it can provide high resolution, target-rich insights for clinicians and patients to better, and less invasively, manage these diseases.
Precision Dose Inc. Issues Voluntary Nationwide Recall of Ranitidine Oral Solution
Enforcement Report - Week of November 8, 2017
Enforcement Report - Week of August 9, 2017
Precision`s Generic Phentolamine mesylate Receives Approval In US